Biogen Gains Rights to Sage Therapeutics’ Zuranolone for $1.53 Billion

Biogen will pay Sage Therapeutics $1.53 billion to jointly develop and sell zuranolone (SAGE-217), a treatment for major depressive disorder (MDD), postpartum depression, and other psychiatric disorders, and SAGE-324, a treatment for essential tremors and additional neurological disorders.

Under the deal, Sage will be eligible to receive future milestone-based payments totaling an estimated $1.6 billion.

An oral tablet meant to be taken daily, zuranolone is currently being evaluated in a U.S. phase 3 study. It previously received a Breakthrough Therapy designation for MDD.